Vinzerex subcutaneous injection 160 mg syringe

Vinzerex subcutaneous injection 160 mg syringe, manufactured by UCB Japan, contains Adalimumab (genetical recombination) [Adalimumab follow-on 3]. Adalimumab is a TNF inhibitor used for the treatment of various autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, and plaque psoriasis. It is available as a 160mg/1mL/1 tube injectable drug (YJ code: 3999464G1020).